EE03741B1 - N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine - Google Patents

N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine

Info

Publication number
EE03741B1
EE03741B1 EE9700310A EE9700310A EE03741B1 EE 03741 B1 EE03741 B1 EE 03741B1 EE 9700310 A EE9700310 A EE 9700310A EE 9700310 A EE9700310 A EE 9700310A EE 03741 B1 EE03741 B1 EE 03741B1
Authority
EE
Estonia
Prior art keywords
aminoindan
propargyl
enantiomer
salts
compositions
Prior art date
Application number
EE9700310A
Other languages
English (en)
Other versions
EE9700310A (et
Inventor
B. H. Youdim Moussa
P. M. Finberg John
Levy Ruth
Sterling Jeffrey
Lerner David
Yellin Haim
Veinberg Alex
Original Assignee
Teva Pharmaceutical Industries, Ltd.
Technion Research And Development Foundation Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23772591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03741(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries, Ltd., Technion Research And Development Foundation Ltd. filed Critical Teva Pharmaceutical Industries, Ltd.
Publication of EE9700310A publication Critical patent/EE9700310A/et
Publication of EE03741B1 publication Critical patent/EE03741B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
EE9700310A 1995-05-22 1996-05-22 N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine EE03741B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/446,439 US5744500A (en) 1990-01-03 1995-05-22 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
PCT/US1996/007465 WO1996037199A1 (en) 1995-05-22 1996-05-22 Use of r-enantiomer of n-propargyl-1-aminoindan, salts, and compositions thereof

Publications (2)

Publication Number Publication Date
EE9700310A EE9700310A (et) 1998-06-15
EE03741B1 true EE03741B1 (et) 2002-06-17

Family

ID=23772591

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700310A EE03741B1 (et) 1995-05-22 1996-05-22 N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine

Country Status (22)

Country Link
US (6) US5744500A (et)
EP (1) EP0828485A4 (et)
JP (1) JP3341898B2 (et)
KR (1) KR100412154B1 (et)
CN (1) CN1096853C (et)
AU (1) AU699090B2 (et)
BR (1) BR9608733A (et)
CA (1) CA2221458A1 (et)
CZ (1) CZ288724B6 (et)
EE (1) EE03741B1 (et)
HK (1) HK1015269A1 (et)
HU (1) HUP9901629A3 (et)
IL (1) IL118247A (et)
LT (1) LT4455B (et)
LV (1) LV12083B (et)
MX (1) MX9708977A (et)
NO (1) NO975331L (et)
NZ (1) NZ308866A (et)
PL (1) PL184124B1 (et)
RU (1) RU2203653C2 (et)
SK (1) SK283675B6 (et)
WO (1) WO1996037199A1 (et)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5877218A (en) * 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5726969A (en) * 1994-12-28 1998-03-10 Matsushita Electric Industrial Co., Ltd. Optical recording medium having dual information surfaces
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
DE60029131T2 (de) 1999-10-27 2007-01-18 Teva Pharmaceutical Industries Ltd. Verwendung von 1-aminoindanderivaten zur behandlung der manie in verbindung mit manisch-depressiver erkrankung
NZ532583A (en) 2001-11-05 2006-12-22 Krele Pharmaceuticals Compositions and methods for increasing compliance using aldehyde dehydrogenase inhibitors ( ALDH ) such as disulfiram and monoamine oxidase B inhibitors ( MAOB ) such as selegiline
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
JP4757024B2 (ja) * 2002-11-07 2011-08-24 テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド 神経保護鉄キレート剤及びそれを含む医薬組成物
PT1567152E (pt) 2002-11-15 2013-10-03 Teva Pharma Uso de rasagilina com riluzol para tratar a esclerose lateral amiotrófica
US20040176430A1 (en) * 2002-11-21 2004-09-09 Jeffrey Sterling Propargyl-trifluoromethoxy-amino-benzothiazole derivatives
CN1605336A (zh) * 2003-10-10 2005-04-13 中国医学科学院药物研究所 左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
JP2007512319A (ja) * 2003-11-25 2007-05-17 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド 心臓血管障害及び疾患を治療するための組成物及び方法
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
US20050197365A1 (en) * 2004-02-27 2005-09-08 Jeffrey Sterling Diamino thiazoloindan derivatives and their use
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
US20060025446A1 (en) * 2004-07-27 2006-02-02 Jeffrey Sterling Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
WO2006014968A2 (en) * 2004-07-27 2006-02-09 Teva Pharmaceutical Industries, Ltd. Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
EP2332408B1 (en) 2005-02-17 2013-11-13 Biogen Idec MA Inc. Treating neurological disorders
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
DK1848415T3 (da) * 2005-02-17 2013-07-08 Teva Pharma Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel sklerose
US7815942B2 (en) 2005-02-23 2010-10-19 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
WO2006091836A1 (en) * 2005-02-24 2006-08-31 Teva Pharmaceutical Industries, Ltd. Formulations of ladostigil tartrate
EP1885388B1 (en) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Treating and evaluating inflammatory disorders
US20060276537A1 (en) * 2005-06-01 2006-12-07 Tamar Goren Use of ladostigil for the treatment of multiple sclerosis
FR2886549B1 (fr) * 2005-06-06 2007-09-07 Biocodex Composition pharmaceutique destinee a la prevention ou au traitement des oedemes cerebraux
US8263655B2 (en) * 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
CA2630037C (en) * 2005-11-17 2015-03-31 Teva Pharmaceutical Industries Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
US20070135518A1 (en) * 2005-12-09 2007-06-14 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
BRPI0620659A2 (pt) * 2005-12-09 2017-10-31 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd método para a prevenção do aparecimento de sintomas de uma doença neurodegenerativa em um indivíduo predisposto à doença neurodegenerativa, método de redução de stress oxidante no cérebro de um indivíduo afligido com stress oxidante, método de tratamento de um indivíduo afligido com a degeneração cognitiva suave e composição farmacêutica
US20110047685A1 (en) * 2006-02-16 2011-03-03 Ferrara Vincent R Impact energy management method and system
JP5701485B2 (ja) 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
NZ571591A (en) * 2006-04-03 2011-09-30 Teva Pharma Use of rasagiline for the treatment of restless legs syndrome
CN101062897B (zh) * 2006-04-25 2011-11-23 重庆医药工业研究院有限责任公司 一种制备2，3-二氢-1h-茚-1-胺及其衍生物的改进方法
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
UA97382C2 (ru) 2006-12-14 2012-02-10 Тева Фармасьютікл Індастріз, Лтд. Таннат разагилина
ES2375761T3 (es) * 2006-12-14 2012-03-06 Teva Pharmaceutical Industries Ltd. Base de rasagilina cristalina sólida.
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EA201070842A1 (ru) * 2008-01-11 2011-04-29 Тева Фармасьютикал Индастриз, Лтд. Препаративные формы разагилина, их получение и применение
WO2009118657A2 (en) * 2008-03-28 2009-10-01 Medichem, S.A. Polymorphic form of an aminoindan mesylate derivative
EP2280929B1 (en) * 2008-06-02 2018-01-31 Generics [UK] Limited An improved process for the preparation of rasagiline
NZ589486A (en) 2008-06-02 2012-08-31 Generics Uk Ltd A process for the preparation of enantiomerically pure 1-(R)-(2-propynylamino)indan
JP2011524353A (ja) * 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
CA2727022A1 (en) * 2008-06-13 2009-12-17 Teva Pharmaceutical Industries Ltd. Rasagiline for parkinson's disease modification
US8334409B2 (en) * 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
CA2727017A1 (en) 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for preparing and drying solid rasagiline base
WO2011012140A2 (en) 2008-07-11 2011-02-03 Synthon Bv Polymorphs of rasagiline hydrochloride
US20110263719A1 (en) * 2008-07-30 2011-10-27 Vinayak Gore Polymorphic form of rasagiline mesylate
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
JP2012523393A (ja) * 2009-04-09 2012-10-04 エム・エス・ディー・オス・ベー・フェー インダン誘導体
DK2451771T3 (da) 2009-07-09 2014-09-08 Ratiopharm Gmbh Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
CN102048717B (zh) † 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2325159A1 (en) 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Novel salts of rasagiline
US8741962B2 (en) * 2009-11-26 2014-06-03 Usv Limited Process for preparation of Rasagiline and salts thereof
WO2011087791A1 (en) 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-keto-n-propargyl-1-aminoindan
HUE044221T2 (hu) 2010-02-03 2019-10-28 Pharma Two B Ltd Nyújtott hatóanyagleadású razagilin készítmények és alkalmazásaik
MY153762A (en) 2010-04-30 2015-03-13 Teikoku Pharma Usa Inc Propynylaminoindan transdermal compositions
EP2598136A4 (en) 2010-07-27 2015-03-25 Teva Pharma DISPERSIONS OF RASAGILINE CITRATE
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
JP6355921B2 (ja) 2010-09-01 2018-07-11 トニックス ファーマスーティカルズ, インコーポレイテッドTONIX Pharmaceuticals, Inc. コカイン嗜癖の治療
CA2816104A1 (en) 2010-10-26 2012-05-03 Teva Pharmaceutical Industries Ltd. Deuterium enriched rasagiline
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
JP5906302B2 (ja) 2011-03-24 2016-04-20 テイコク ファーマ ユーエスエー インコーポレーテッド 作用剤層および作用剤変換層を含む経皮組成物
BR112014008555A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-formil-propargil-aminoindano
MX2014004201A (es) * 2011-10-10 2015-01-12 Teva Pharma R(+)-n-metil-propargil-aminoindano.
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
WO2013139387A1 (en) 2012-03-21 2013-09-26 Synthon Bv Stabilized pharmaceutical compositions comprising rasagiline salts
WO2013175493A1 (en) 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
WO2014028868A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline
CA2887705C (en) 2012-11-02 2018-07-24 Teikoku Pharma Usa, Inc. Propynylaminoindan transdermal compositions
ES2524865T1 (es) * 2013-02-06 2014-12-15 Galenicum Health S.L. Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata
EP2764862A1 (en) * 2013-02-06 2014-08-13 Galenicum Health S.L. Immediate release tablets of rasagiline hemitartrate
JP2016512231A (ja) * 2013-03-13 2016-04-25 エヌ ティーオー ビー リミテッドＮ Ｔｏ Ｂ Ｌｔｄ． パーキンソン病に伴う運動及び抑うつ症状の治療方法、組成物及び装置
CN103804200B (zh) * 2014-02-21 2015-04-29 常州市第四制药厂有限公司 雷沙吉兰及其类似物的制备方法
US11701340B2 (en) * 2019-04-17 2023-07-18 Vici Health Sciences., Llc Liquid pharmaceutical compositions

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) * 1965-08-17 Chsx c cech
US513244A (en) * 1894-01-23 Island
US3253037A (en) * 1962-06-19 1966-05-24 Ciba Geigy Corp N-2-alkynyl-amino-benzocylo-alkanes
GB1187017A (en) 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
GB1037014A (en) 1963-08-02 1966-07-20 Aspro Nicholas Ltd Derivatives of 1-aminoindane
US3513249A (en) * 1968-12-24 1970-05-19 Ideal Ind Explosion connector with improved insulating means
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
ES2042520T3 (es) * 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
DE3781627T2 (de) 1986-08-21 1993-05-06 Roussel Uclaf Indanderivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, diese enthaltende pharmazeutische zusammensetzungen und erhaltene zwischenprodukte.
HU197510B (en) 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
ZA885824B (en) 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
FR2626877B1 (fr) 1988-02-05 1991-04-05 Delalande Sa Ethers alkyliques ou benzyliques du phenol, leurs procedes de preparation et leur application en therapeutique
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
GB8909793D0 (en) 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
WO1991004479A1 (en) 1989-09-25 1991-04-04 The United States Of America, Represented By The Secretary, United States Department Of Commerce Evaluative means for detecting inflammatory reactivity and for predicting response to stress
DK0494972T3 (da) 1989-10-02 1997-05-12 Cima Labs Inc Brusedosisform samt fremgangsmåde til administration heraf
FR2655044B1 (fr) 1989-11-24 1995-03-03 Delalande Sa Derives d'(hetero) arylmethyloxy-4 phenyl tetrazole et oxadiazole, leur procede de preparation et leur application en therapeutique.
JPH03176457A (ja) 1989-12-04 1991-07-31 Nippon Paint Co Ltd 新規プロパルギル化合物、その製法ならびに該化合物を含む被覆材
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
CA2039742A1 (en) 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials
US5169868A (en) 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5767164A (en) * 1991-04-04 1998-06-16 Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
IL112819A (en) 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
EP0651997B1 (en) 1991-12-24 1998-10-28 Yamanouchi Pharmaceutical Co. Ltd. Intrabuccally disintegrating preparation and production thereof
US5298261A (en) 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
WO1993025197A1 (en) 1992-06-12 1993-12-23 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
SE501848C2 (sv) 1992-11-18 1995-06-06 Kvaerner Pulping Tech Metod att koka massa kontinuerligt vid konstant temperatur
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL112779A (en) 1994-03-01 1999-11-30 Gergely Gerhard Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
GEP20012374B (en) 1995-03-02 2001-03-25 Scherer Ltd R P Pharmaceutical Compositions Comprising Monoamine Oxidase B Inhibitors, Method for Obtaining the Same and Use
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
EP1052983A2 (en) * 1998-01-27 2000-11-22 Thomas N. Thomas Use of an mao-a or mao-b inhibitor for the treatment of vascular disorders
FI104042B (fi) * 1998-09-29 1999-11-15 Aaro Kiuru Menetelmä keuhkojen perfuusion mittaamiseksi
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2003011255A1 (en) * 2001-07-04 2003-02-13 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20060009483A1 (en) * 2002-05-31 2006-01-12 Bayer Pharmaceuticals Corporation Compounds and compositions for the treatment of diabetes and diabetes-related disorders
AU2003288902A1 (en) * 2002-09-06 2004-04-08 Genteric, Inc. Microcapsules and methods of use
PT1567152E (pt) * 2002-11-15 2013-10-03 Teva Pharma Uso de rasagilina com riluzol para tratar a esclerose lateral amiotrófica
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
US7815942B2 (en) * 2005-02-23 2010-10-19 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity

Also Published As

Publication number Publication date
RU2203653C2 (ru) 2003-05-10
BR9608733A (pt) 1999-12-07
SK157497A3 (en) 1998-05-06
US20030212145A1 (en) 2003-11-13
CZ369997A3 (cs) 1999-06-16
LT97200A (en) 1998-09-25
KR100412154B1 (ko) 2004-07-05
EP0828485A1 (en) 1998-03-18
US6956060B2 (en) 2005-10-18
EE9700310A (et) 1998-06-15
WO1996037199A1 (en) 1996-11-28
WO1996037199A8 (en) 1999-08-12
LT4455B (lt) 1999-01-25
PL184124B1 (pl) 2002-09-30
JP2000508292A (ja) 2000-07-04
SK283675B6 (sk) 2003-11-04
US5744500A (en) 1998-04-28
CN1191481A (zh) 1998-08-26
JP3341898B2 (ja) 2002-11-05
US20070100001A1 (en) 2007-05-03
EP0828485A4 (en) 1998-12-02
AU699090B2 (en) 1998-11-19
HUP9901629A3 (en) 2000-03-28
CZ288724B6 (cs) 2001-08-15
LV12083B (en) 1998-09-20
IL118247A (en) 2002-07-25
NO975331L (no) 1998-01-20
NZ308866A (en) 1999-09-29
HK1015269A1 (en) 1999-10-15
NO975331D0 (no) 1997-11-20
HUP9901629A2 (hu) 2000-02-28
MX9708977A (es) 1998-03-31
US20060094783A1 (en) 2006-05-04
US20030065038A1 (en) 2003-04-03
PL323470A1 (en) 1998-03-30
US6316504B1 (en) 2001-11-13
US6630514B2 (en) 2003-10-07
IL118247A0 (en) 1996-09-12
CA2221458A1 (en) 1996-11-28
KR19990021896A (ko) 1999-03-25
AU5872396A (en) 1996-12-11
CN1096853C (zh) 2002-12-25
LV12083A (lv) 1998-07-20

Similar Documents

Publication Publication Date Title
EE03741B1 (et) N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine
EE200000468A (et) Ühendid, nende kasutamine ja farmatseutiline kompositsioon
EE9900018A (et) Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
FI955235A0 (fi) Oksatsolidiinionijohdannaiset, niiden valmistus ja käyttö
EE03486B1 (et) Pürasool-4-üülbensoüüli derivaadid ja nende kasutamine herbitsiididena
DE19681287T1 (de) Orale Formulierung von 2-Methylthienobenzodiazepin
FI973828A (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
NL300295I2 (nl) 3,3-diarylpropylaminen, de toepassing en bereidinghiervan
BR9508677A (pt) Copolímero prodesso de preparação do mesmo e composição orgânica
EE04500B1 (et) Trombiini inhibiitorid, nende saamine ja kasutamine
EE200000037A (et) Atsüülpiperasinüülpürimidiinide derivaadid, nende valmistamine ja kasutamine ravimitena
EE200000621A (et) Pikornaviirusevastased ühendid, nende valmistamine ja kasutamine
FI962908A (fi) Mikrobinvastainen koostumus, sen valmistusmenetelmä ja sen käyttö
ITRM940002A0 (it) Composizione orale.
EE200000226A (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
EE200100347A (et) 3,3-biarüülpiperidiini ja 2,2-biarüülmorfoliini derivaadid
EE9900524A (et) N-triasolüül-2-indoolkarboksamiidid ja nende kasutamine CCK-A agonistidena
FI964031A (fi) Bentsamidijohdannainen, mainittua johdannaista sisältävät koostumukset ja sen käyttö
EE9900034A (et) Arüültsükloalkaankarboksüülestrid, nende kasutamine, farmatseutilised kompositsioonid ja valmistamine
FI972306A0 (fi) Substituoituja 2-aryylikarbonyylioksimetyyli-1,2,5-tiadiatsolidin -3- oni-1,1-dioksidi-johdannaisia ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
FI973229A (fi) Uusi farmaseuttinen koostumus
FI955679A0 (fi) Piperidiinijohdannaisia, niiden valmistus ja käyttö
FI961977A (fi) N-substituoidut atsabisykloalkaanijohdannaiset, niiden valmistus ja käyttö
DE69300492D1 (de) Orale Zusammensetzung.
EE9800054A (et) Pürasool-4-üül-bensoüüli derivaadid ja nende kasutamine herbitsiididena

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

AA1Y Spc filed

Free format text: PRODUCT NAME: AZILECT; REG NO/DATE: (EMEA/H/C/574) 21.02.2005

Spc suppl protection certif: C20050006

Filing date: 20050822

FG1Y Spc granted

Free format text: PRODUCT NAME: AZILECT; REG NO/DATE: (EMEA/H/C/574) 21.02.2005

Spc suppl protection certif: C20050006 00009

Filing date: 20050822

Extension date: 20190221

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

MC1Y Annulment of an spc

Spc suppl protection certif: 00009

MM4A Lapsed by not paying the annual fees

Effective date: 20070522